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The emergence of bacterial resistance to the most commonly used antibiotics
encourages the design of novel antimicrobial drugs. Antimicrobial proteins and peptides
(AMPs) are the key players in host innate immunity. They exert a rapid and multifaceted
action that reduces the development of bacterial adaptation mechanisms. Human
antimicrobial RNases belonging to the vertebrate specific RNase A superfamily
participate in the maintenance of tissue and body fluid sterility. Among the eight human
canonical RNases, RNase 3 stands out as the most cationic and effective bactericidal
protein against Gram-negative species. Its enhanced ability to disrupt the bacterial
cell wall has evolved in detriment of its catalytic activity. Based on structure-functional
studies we have designed an RNase 3/1 hybrid construct that combines the high
catalytic activity of RNase 1 with RNase 3 bactericidal properties. Next, we have
explored the ability of this hybrid RNase to target the development of bacterial
resistance on an Acinetobacter baumannii cell culture. Synergy assays were performed
in combination with colistin, a standard antimicrobial peptide used as an antibiotic
to treat severe infections. Positive synergism was observed between colistin and the
RNase 3/1 hybrid protein. Subsequently, using an in vitro experimental evolution assay,
by exposure of a bacterial culture to colistin at incremental doses, we demonstrated the
ability of the RNase 3/1 construct to reduce the emergence of bacterial antimicrobial
resistance. The results advance the potential applicability of RNase-based drugs as
antibiotic adjuvants.
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INTRODUCTION
The emergence of bacterial resistance to conventional antibiotics is becoming a serious sanitary
and economical threat. There is an urgent need to develop alternative drugs that address
this global health issue and overcome the spread of infectious diseases (Lohrasbi et al., 2018;
Mustazzolu et al., 2018). In particular, novel therapeutic approaches will be required to fight
the dissemination of multi-drug resistant bacterial strains that threaten our public health system
to return to the “pre-antibiotic era” (Wright, 2016). Currently, the majority of antimicrobial
agents that are available in the pharmaceutical market rely on the direct elimination of the
microorganisms. Notwithstanding, recent literature highlights the potentiality of drug combination
and simultaneous targeting of diverse cellular processes (Brochado et al., 2018; Lázár et al., 2018) to
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overcome the bacterial development of resistance mechanisms.
Being aware that full eradication of antibiotic resistance might
be unattainable, we should gather all our available means to
minimize its dissemination and impact. One of the favorite
strategies to overcome the so called “antibiotic resistance
era” relies on the discovery of unconventional drugs and
combinatorial approaches (Brown and Wright, 2016).
In the search of novel antibiotic candidates, our own
innate immunity system represents one of the best reservoirs.
Upon infection, our innate immune cells secrete a variety of
antimicrobial proteins and peptides (AMPs) that protect the host
biological fluids against pathogen invasion. AMPs are usually
small polypeptides that present a non-specific wide-spectrum
targeting of microorganisms (Hancock and Diamond, 2000).
A growing clinical interest for AMPs is derived from their
low toxicity to mammalian cells, together with the fact that
bacterial resistance to these molecules seems inherently more
difficult to acquire in comparison to conventional antibiotics
(Lai and Gallo, 2009; Nakatsuji and Gallo, 2012; Casciaro et al.,
2018). Within the AMPs, the largest group corresponds to
cationic peptides (Hancock and Diamond, 2000). The mode of
action of cationic antimicrobial peptides is different from that
of conventional antibiotics and is often related to interaction
with bacterial walls through electrostatic forces and subsequent
cell lysis (Yeaman, 2003; Bahar and Ren, 2013). AMPs are
mostly amphiphilic in nature and they are comprised of
hydrophobic and hydrophilic residues aligned on opposite sides
of the peptides, facilitating their easy penetration through cell
membranes (Torrent et al., 2011a,b; Brandenburg et al., 2012).
Fortunately, although several cases of bacterial resistance to
AMPs have been observed (Perron et al., 2006; Moffatt et al.,
2010), the complex structure of bacterial envelopes hinder the
development of total resistance. Besides, AMPs are frequently
multifaceted molecules that combine a direct mechanical action
to the bacterial envelope with a specific enzymatic activity
that targets essential intracellular macromolecule components.
A variety of multifunctional antimicrobial proteins, endowed
with protease, DNase or RNase activity, can participate in the host
defense system (Brogden, 2005; Hancock and Sahl, 2006; Boix
and Nogués, 2007; Arranz-Trullén et al., 2017).
In our laboratory, we are working on the structure-functional
relationship of human antimicrobial RNases that belong to
the vertebrate-specific RNase A superfamily and are secreted
by epithelial and blood cells during infection (Gupta et al.,
2012; Koczera et al., 2016; Lu et al., 2018). Characterization
of the mechanism of action of human antimicrobial RNases
suggests that a combination of activities are taking place (Salazar
et al., 2016; Lu et al., 2018). In particular, the human RNase 3,
mostly secreted by eosinophils upon infection, combines a high
cationicity (pI ∼11), lipopolysaccharide (LPS) binding affinity,
membrane destabilization and bacterial agglutination activities
(Boix et al., 2012; Torrent et al., 2012).
Interestingly, a striking structural homology between the
RNase A superfamily and bacterial RNases belonging to the
contact-dependent growth inhibition (CDI) toxins was recently
reported (Batot et al., 2017; Cuthbert et al., 2018). CDI bacterial
toxins work as inter-strain competition weapons and use the
RNase enzymatic activity as a self-defense mechanism. Indeed,
most of our current antibiotics are derived from natural
compounds produced by microorganisms against competing
species (Blair et al., 2015). Among them, bacteriocins, expressed
by commensal species and endowed with enzymatic activities,
are being considered as appealing alternative antibiotics to fight
pathogenic strains (Mathur et al., 2018).
Another alternative approach proposed to fight resistance
mechanisms against antimicrobial agents is the targeting of
the bacterial community integrity. Recent studies reveal the
previously underestimated complexity of bacterial communities
and identify collective resistance mechanisms (Vega and Gore,
2014). Novel strategies can be engineered to target the
bacterial community cohesion and thereby weaken collective
resistance. Collective resistance ensures the survival of the
microbial community upon exposure to antibiotic conditions
that otherwise would be lethal to individual bacterial cells (Vega
and Gore, 2014). One of the main mechanisms that ensures
bacterial survival relies on the intercellular horizontal transfer
of information that facilitates a rapid response to any external
injury and ensures the community’s adaptation to a hostile
environment (Papenfort and Bassler, 2016). Recent discoveries
have identified signaling molecules that contribute to community
quorum sensing, such as regulatory small RNAs (Papenfort
and Vogel, 2010). Therefore, an antimicrobial agent endowed
with RNase activity that can target bacterial quorum-sensing
signaling might work as an antibiotic adjuvant. Indeed, the use of
antibiotic adjuvants is one of the selected strategies to minimize
the emergence and impact of resistance phenomena (Wright,
2016). Addition of adjuvants can lower the needed antibiotic
dose to reach a therapeutic effect (Brown and Wright, 2016).
Moreover, weakening the bacterial community cohesion would
reduce the emergence and dissemination of resistant pathogenic
strains (Starkey et al., 2014).
In this study, we have committed ourselves to evaluating the
potential contribution of RNase catalytic activity in reducing the
emergence of bacterial resistance. Toward this end, we have used
an experimental evolution assay by exposing an Acinetobacter
baumannii bacterial culture to increasing concentrations of
colistin. Colistin (also called polymyxin E) is a non-ribosomal
bacterial cyclic AMP only used in the clinics as a last resort
to treat live-threatening infections, due to its reported toxicity.
Here, we have tested the reduction of the antimicrobial resistance
against colistin upon treatment with an engineered RNase




The A. baumannii strain (CECT 452; ATCC 19606) and
Pseudomonas aeruginosa strains (CECT 4122; ATCC 15692)
are from the Spanish Type Culture Collection (CECT). The
Escherichia coli BL21(DE3) strain and the pET11c plasmid are
from Novagen. MRC-5 and HepG2 cells are from the American
Type Cell Culture Collection (ATCCC). Mueller–Hinton broth,
Frontiers in Microbiology | www.frontiersin.org 2 June 2019 | Volume 10 | Article 1357
fmicb-10-01357 June 18, 2019 Time: 16:0 # 3
Prats-Ejarque et al. An Antimicrobial RNase Targeting Bacterial Resistance
LPS and RNase A (Type XII) are from Sigma-Aldrich.
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
(MTT), Isopropyl β-D-1-thiogalactopyranoside (IPTG) and
colistin are from Apollo Scientific. 1-aminonaphthalene-3,6,8-
trisulfonate (ANTS), α,α′-dipyridinium p-xylene dibromide
(DPX) and the fluorescent probe BODIPY TR cadaverine
are from Molecular Probes. Toludine blue is from Merck.
RNase 3/1 gene was purchased from NZYTech. 1,2-dioleoyl-sn-
glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-
3-phosphoglycerol (DOPG) were from Avanti Polar Lipids. E. coli
lipid extract was obtained as described (Folch et al., 1957).
Human RNase 1 gene was a gift from Dr. Maria Vilanova,
Universitat de Girona, Spain, and human RNase 3 sequence was
taken from a previously synthesized gene (Boix et al., 1999).
Protein Expression and Purification
The RNase 1, 3, and 3/1 genes were subcloned into the plasmid
pET11c for prokaryote high yield expression in the E. coli
BL21(DE3) strain. The recombinant protein was expressed
and purified as previously described (Boix, 2001), with some
modifications (Palmer and Wingfield, 2004). Briefly, bacteria
were grown in terrific broth (TB), containing 400 µg/mL
ampicillin. Recombinant protein was expressed after cell
induction with 1 mM IPTG added when the culture showed
an OD600 of 0.6. The cell pellet was collected after 4 h of
culture at 37◦C. Cells were resuspended in 10 mM Tris/HCl
and 2 mM EDTA, pH 8 and 40 µg/mL of lysozyme, and
sonicated after 30 min. The pellet was suspended in 25 mL
of the same buffer with 1% triton X-100 and 1 M urea and
was left stirring at room temperature for 30 min, before being
centrifuged for 30 min at 22.000× g. This procedure was repeated
until the supernatant was completely transparent. In order to
remove the triton X-100, 200 mL of 10 mM Tris-HCl pH 8.5,
2 mM EDTA was added to the pellet and centrifuged again
for 30 min at 22.000 × g. The resulting pellet was suspended
in 25 mL of Tris-acetate 100 mM, pH 8.5, 2 mM EDTA, 6
M guanidine hydrochloride, and 80 mM of DTT. The protein
was then refolded for 72 h at 4◦C by a rapid 100-fold dilution
into 100 mM Tris/HCl, pH 8.5, 0.5 M of guanidinium chloride,
and 0.5 M L-arginine, and oxidized glutathione (GSSG) was
added to obtain a DTT/GSSG ratio of 4. The folded protein
was then concentrated, buffer-exchanged against 150 mM sodium
acetate, pH 5 and purified by cation-exchange chromatography
on a Resource S (GE Healthcare) column equilibrated with the
same buffer. The protein was eluted with a linear NaCl gradient
from 0 to 2 M in 150 mM sodium acetate, pH 5. The protein
purity was checked by SDS-PAGE and reverse-phase HPLC.
Absence of unpaired Cys was confirmed by the Ellman’s reaction
(Ellman, 1959).
Circular Dichroism (CD)
Far-UV CD spectra were obtained from a Jasco-715 (Jasco), as
previously described (Torrent et al., 2009a). The spectra were
registered from 195 to 240 nm at room temperature. Data from
four consecutive scans were averaged. Before reading, the sample
was centrifuged at 10.000 × g for 5 min. Protein spectra were
obtained at 6 µM in 5 mM sodium phosphate, pH 7.5, with a
0.2 cm path-length quartz cuvette. The percentage of secondary
structure was estimated with Spectra Manager II, as described
(Yang et al., 1986).
Activity Staining Gel
Zymograms were performed following the method previously
described (Bravo et al., 1994). 15% polyacrylamide-SDS gels were
cast with 0.3 mg/mL of poly(C) (Sigma Aldrich). Then, 20 ng
of RNase 1, 3, and 3/1 were loaded, and the gel was run at a
constant current of 100 V for 1.5 h. Following, the SDS was
removed from the gel with 10 mM Tris/HCl, pH 8, and 10%
(v/v) isopropanol. The gel was then incubated during 1 h in
the activity buffer (100 mM Tris/HCl, pH 8) to allow enzymatic
digestion of the embedded substrate and then stained with 0.2%
(w/v) toluidine blue in 10 mM Tris/HCl, pH 8, for 10 min.
Positive bands appeared white against the blue background. The




MBC100 was defined as the lowest protein/peptide concentration
that completely eradicated bacterial cells. RNase 3/1 was serially
diluted in HBS (HEPES 20 mm pH 7.4, NaCl 100 mM) in 96-well
plate in a volume of 100 µL to achieve final concentrations from
20 to 0.02 µM. Then, 2 µL of an exponential phase subculture
of E. coli, A. baumannii or P. aeruginosa was added, previously
adjusted to give a final concentration of approximately 5 × 105
colony-forming units (CFU)/mL in each well and the plate was
incubated for 4 h at 37◦C and 100 rpm. Finally, samples were
plated onto LB (Condalab) Petri dishes and incubated at 37◦C
overnight. All the assays were performed in triplicate.
Cytotoxicity Assay
Cytotoxicity was measured for the MRC-5 and HepG2 human
cell lines using the MTT assay, as described previously (Pulido
et al., 2018). Cells were grown in 5% CO2 at 37 ◦C with minimal
essential medium supplemented with 10% fetal bovine serum
(FBS). Cells were plated at 5× 104 cells/well in a 96-well plate and
incubated overnight. Next, the medium was removed and serial
dilutions of RNase 1, 3, and 3/1 were added at concentrations
ranging from 200 to 0.2 µM in 100 µL of medium without
serum. After 4 h of incubation, the medium was replaced with
fresh medium containing 0.5 mg/mL MTT solution and the
mixture was incubated for 2 h in 5% CO2 at 37 ◦C. The medium
was then removed and formazan was dissolved by adding acidic
isopropanol. The optical density (OD) was recorded by using a
Victor3 plate reader (PerkinElmer, Waltham, MA) set at 550 and
630 nm as references. Reference absorbance at 630 nm was used
to correct for nonspecific background values. Each experiment
was repeated at least three times.
LPS Binding Assay
The LPS-binding affinity was assessed using the fluorescent probe
BODIPY TR cadaverine (BC) as described (Torrent et al., 2008).
RNase 1, 3, and 3/1were serially diluted in a 96-well fluorescence
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plate from 20 to 0.02 µM in HEPES 10 mm pH 7.4. Then,
LPS (10 µg/mL) and BC (10 µM) were added in the same
buffer. Fluorescence measurements were performed on a Victor3
plate reader. The BC excitation wavelength was 580 nm, and
the emission wavelength was 620 nm. Occupancy factor was
calculated as described previously (Torrent et al., 2008).
Liposome Preparation
Large unilamellar vesicles (LUVs) containing DOPC/DOPG (3:2
molar ratio, 1 mM stock concentration) or E. coli membrane
lipids (5 mg/mL stock concentration) of a defined size were
obtained from a vacuum drying lipid chloroform solution. After
the chloroform evaporation, liposomes were suspended with
10 mM Tris/HCl, 20 mM NaCl, pH 7.4. The distribution and the
mean hydrodynamic range of the liposomes in suspension was
determined by dynamic light scattering (DLS) with a Zetasizer
Nano ZS Malvern, and the data was analyzed by its built-in
software (Zetasizer 7.02).
Liposome Leakage
The ANTS/DPX liposome leakage fluorescence assay was
performed as previously described (Pulido et al., 2016a). Briefly,
a unique population of LUVs DOPC/DOPG (3:2) or E. coli
liposomes was prepared to encapsulate a solution containing
12.5 mM ANTS, 45 mM DPX, 20 mM NaCl, and 10 mM
Tris/HCl, pH 7.5 by applying three freeze-thaw cycles. The
ANTS/DPX liposome stock suspension was diluted to 30 µM
and incubated at 37◦C for 1 h with RNase 1, 3, and 3/1, serially
diluted from 20 to 0.015 µM in a microtiter fluorescence plate.
Fluorescence measurements were performed on a Victor3 plate
reader with an excitation wavelength of 386 nm and an emission
wavelength of 535 nm. ED50 values were calculated by fitting the
data to a dose–response curve with Origin 8.0.
Synergy Determination Assay
The synergy test was carried out by determining the bacterial
minimum inhibitory concentration (MIC) in Müller Hinton
medium, as follows. 8 × 8 well plates were used to check
the protein/colistin combinations. First, RNase 3/1 was serially
diluted from 12 to 0.1 µM, in eppendorf tubes at a 10-fold
the final concentration in 0.01% acetic acid (Wiegand et al.,
2008). Then, colistin was serially diluted from 8 to 0.02 µM
in Mueller–Hinton medium to a final volume of 90 µL, and
10 µL of the serially diluted protein aliquots were added in each
corresponding well (except in the negative control, where only
buffer was added). After that, 2 µL of a 1:3 diluted 24-h culture of
A. baumannii were added to each well to achieve a final 1:150
bacterial dilution (approximately 2 × 105 CFU/mL), and the
plate was incubated overnight at 37◦C and 100 rpm. Positive or
negative bacterial growth was checked by optical density. All the
assays were performed in triplicate.
Antimicrobial Resistance Evolution
Assay by Colistin Exposure
A fresh and isolated colony of A. baumannii was picked up
and left to grow overnight in Mueller–Hinton broth. The
next day, the 24-h culture (stationary phase) was diluted
1:150 times (approximately 2 × 107 CFU/mL) and placed
in a 96-well polypropylene plate. Before the inoculation of
the bacteria, 90 µL of colistin in Mueller–Hinton medium
were added to 80 wells in order to achieve the desired
concentration in the final volume (100 µL). To 40 of these
wells, 10 µL of 1 µM RNase 3/1 (to have a final concentration
of 100 nM) in a cationic protein/peptide stabilizer solution
(acetic acid at 0.01%) was added (Wiegand et al., 2008).
To the other 40 wells, the same solution without protein
was added. Finally, Mueller–Hinton medium with 10% of the
stabilizer solution was added to the other 16 wells, as a
negative control.
In the first experiment (Assay 1), the plate was placed
overnight in an Infinite F Nano + (Tecan) plate reader
at 37◦C with orbital shaking, and the OD600 was recorded
every 5 min. The day after, the cultures at the stationary
phase were diluted three times and 2 µL of the diluted
bacteria were inoculated to a new plate prepared as explained
above, in order to have a 1:150 final dilution and incubated
overnight to determine the bacterial growth profiles by DO600nm
monitoring. The first plate was stored at −80◦C with 15%
of glycerol for later determination of colistin MIC value. The
dose of each day of colistin exposure was adjusted according
to the observed bacterial growth; when no reduction of
the bacterial growth was observed, the dose was increased;
and, when bacteria growth reduction was observed, the
dose was maintained.
In order to test if RNase 3/1 could also hinder the resistance
acquisition of the bacteria in a colistin-pre-exposed strain, a
second assay was performed, following a modification of a
previously described assay (Lázár et al., 2018) (named as Assay
2). The plate preparation was performed as previously explained
with the following modifications. Before starting the treatment
protocol, a fresh isolated colony of A. baumannii was preexposed
for three 24-h cycles to a 0.3 µM initial dose of colistin at the
same conditions than the first exposure assay. Then, to each of
40 wells of the pre-exposed culture, the protein was added to
a concentration of 1 µM, while the colistin dose was increased
at 1.2 × serial incremental doses, keeping constant the protein
concentration. The plates were incubated in an incubator at
37◦C and 100 rpm. The OD600 was recorded after 24 h in a
Victor3 plate reader.
Minimum Inhibition Concentration (MIC)
Determination
The MIC of each of the bacterial lineages generated during the
resistance evolution assay was determined. MIC was defined
as the lowest protein/peptide concentration that completely
inhibited bacterial growth. Colistin was serially diluted from 64
to 0.5 µM in Mueller–Hinton. Next, 2 µL of a 1:3 diluted 24-h
culture of each A. baumannii lineage were added to each well to
achieve a final 1:150 bacterial dilution (approximately 2 × 107
CFU/mL), and the plate was incubated overnight at 37◦C and
100 rpm. Presence or absence of bacterial growth were checked
by visual inspection.
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Statistical Analysis
Barlett’s test and Shapiro–Wilk’s method were used to study
the variance homogeneity and normal distribution of the
data, respectively. Due to unequal sample size among groups
(unbalanced design), the Kruskall-Wallis non-parametric test
followed by post hoc comparisons using Wilcoxon method were
used for statistical comparison of continuous variable (time to
reach exponential phase) for A. baumannii between and within
the three different groups (culture bacteria treated with colistin,
colistin+ RNase 3/1 or non-treated control). Sample size (n) was
40 for the two treatments and 16 for the control group. Statistical
significance was set at p < 0.05, and all statistical tests were
2-sided. Data are presented as means± standard error. Statistical
analysis and data visualization was performed using R Software
3.4.4 (R Core Team, 2018).
RESULTS
RNase 3/1 Rational Design
RNase 3/1 has been designed in an effort to combine both
the high bactericidal activity of human RNase 3 and the high
catalytic activity of human RNase 1, according to previous
structural-functional studies (Prats-Ejarque et al., unpublished
results). Using the RNase 1 structure as a scaffold, antibacterial
regions of RNase 3 were added. Specifically, we incorporated the
N-terminal region of RNase 3, previously found to be related to
antimicrobial activity (Torrent et al., 2009a, 2010, 2013; Sánchez
et al., 2011), but preserved the Asp17-Ser26 flexible loop of
RNase 1, considered essential for RNase 1 high catalytic activity
(Doucet et al., 2009; Gagné et al., 2015). In addition, the cationic
regions from Arg77 to Arg81 and Arg103 to Arg107, associated to
RNase 3 bactericidal activity, were incorporated (Carreras et al.,
2003). On the other hand, the residues that participate in the
binding of the main and secondary bases of the RNA substrate,
located at the 5′ and 3′ sides of the cleaved phosphodiester bond
(B1 and B2, respectively), were kept according to the RNase 1
sequence. The resulting final sequence and the structure model
are shown in Figure 1.
RNase 3/1 was successfully expressed in E. coli BL21(DE3) cells
and purified from inclusion bodies at a final yield of 30 mg/L
of bacterial culture. The proper 3D protein folding was checked
by circular dichroism (Supplementary Figure S1), giving the
characteristic secondary structure percentage distribution of the
RNase A family (Fowler et al., 2011). Moreover, we confirmed
by Ellman’s assay that all disulphide bonds were formed in
the refolded protein and no free Cys residue was present
(A412 nm = 0.0003 and 0.001 for 4 and 8 µM of protein sample
respect to control buffer).
Next, we assessed the protein catalytic activity using an activity
staining gel. Results indicated that the RNase 3/1 hybrid displays
a high catalytic efficiency toward a polynucleotide substrate.
As shown in Figure 2, the catalytic activity of RNase 3/1 for
polyuridine (poly(U)) is more than 30 times higher than that of
RNase 3, almost reaching half of the catalytic activity of RNase 1.
In view of these results, we wanted to check whether the
engineered structural changes that achieved an increase in
catalytic activity in relation to RNase 3 had any detrimental
effect on the hybrid proteins antimicrobial activity. Therefore,
we determined the MBC for the hybrid and parental RNases.
FIGURE 1 | Design of RNase3/1 chimera. (A) Model of RNase 3/1 obtained by Modeler 9.12 (Webb and Sali, 2016). In green, B1 site. In pink, B2 site. In red, the
active site. In beige, the RNase 1 skeleton. In light blue, the RNase 3 antimicrobial regions. (B) Alignment of RNase 1, 3 and 3/1 primary structures. The fully
conserved amino acids are highlighted in red. The residues that are not conserved but have similar properties are marked with red letters. The secondary structure is
indicated above the alignment. The green numbers indicate the disulphide bridge pairs. The alignment was done using Clustal Omega (Sievers and Higgins, 2018),
and the image was obtained with ESPript7 (http://espript.ibcp.fr/ESPript/) (Robert and Gouet, 2014).
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FIGURE 2 | Catalytic characterization of RNase3/1 by zymogram. (A) Activity staining gel showing the degradation of poly(U) with 20 ng of each protein. RNase 3
(lane 1), RNase 3/1 (lane 2), and RNase 1 (lane 3). (B) Densitometric analysis of the bands of the activity staining gel. Quantification was done from a scan image
using Quantity One software (Bio-Rad R©).
The results confirmed the acquisition of bactericidal activity of
RNase 3/1 respect to the non-antimicrobial RNase 1; although
a significant decrease of the hybrid bactericidal activity in
comparison to RNase 3 is appreciated (Table 1).
Next, we evaluated whether our protein construct retained
the high LPS-binding affinity observed for RNase 3 (Torrent
et al., 2008; Pulido et al., 2012, 2016b). LPS-binding affinity
was estimated by a displacement assay using the fluorescent
BODIPY-cadaverine (BC) probe as previously described (Torrent
et al., 2008). Results confirmed that RNase 3/1 retained
a similar LPS-binding affinity to RNase 3 (Table 2 and
Supplementary Figure S2).
In addition, the liposome leakage ability of the RNases was
evaluated. As shown in Table 2, RNase 3/1 retains similar
liposome leakage activity to RNase 3, while RNase 1 does not
present any membrane disruption ability.
Finally, the potential cytotoxicity against host tissues was
evaluated in vitro using two human cell lines: immortalized lung
fibroblasts (MRC-5) and tumor hepatic cells (HepG2). The results
indicated that RNase 3/1 shows no toxicity at the maximum
concentration tested (200 µM) as observed for RNase 1 (Table 3).
RNase 3/1 Shows Synergy Activity With
Colistin Against A. baumannii
Next, we decided to test the potential synergistic activity of
RNase 3/1 in combination with a common antimicrobial peptide
TABLE 1 | Bactericidal activity characterization of RNase3/1.
MBC100 (µM)
E. coli A. baumannii P. aeruginosa
RNase 1 >20 >20 18.33 ± 2.89
RNase 3 1.88 ± 0.88 0.6 ± 0.07 0.6 ± 0.07
RNase 3/1 6.25 ± 2.17 6.25 ± 2.17 3.13 ± 1.08
MBC100 was determined as the lowest concentration of peptide where no cells
were detected by Colony Forming Units counting in HBS solution.







RNase 1 1.50 ± 0.28 N.D. N.D.
RNase 3 0.38 ± 0.03 1.19 ± 0.19 1.87 ± 0.42
RNase 3/1 0.59 ± 0.02 1.18 ± 0.36 0.86 ± 0.18
The LPS binding concentration at the 50% displacement (LBC50) values have
been determined from a dose-response curve adjusted by OriginPro 8 statistical
software. Liposome leakage was measured as the protein concentration that
induces 20% of liposome leakage (LC20). Experimental data plots are shown in
Supplementary Figures S2, S3, respectively. N.D. indicates that no leakage was
detected at the highest tested concentration (20 µM).
TABLE 3 | Cytotoxic activity characterization of RNase3/1.
IC50 (µM)
RNase 1 RNase 3 RNase 3/1
Lung fibroblasts (MRC-5) N.D. >100 N.D.
Hepatocarcinoma epithelial
cells (HepG2)
N.D. 134.66 ± 0.95 N.D.
IC50 was determined as the concentration of protein where 50% of cells were still
alive. Cytotoxicity was determined by the MTT assay. Each assay was performed
in triplicate. N.D. means that, at the highest tested concentration (200 µM), no
reduction of cell viability was detected.
used in the clinics, colistin. The analysis of the combinatorial
effect of RNase 3/1 with colistin showed that the combination
of colistin with RNase 3/1 improves significantly the MIC100 of
colistin against A. baumannii (Figure 3). The MIC100 value for
colistin alone in the assayed conditions was 0.9 ± 0.05 µM.
The calculated RNase 3/1 concentration where the MIC for
colistin is reduced by half was 1.35 ± 0.15 µM. Interestingly,
we observe a biphasic dose-response profile, where the MIC for
colistin reaches a first plateau in the presence of 0.3 to 5 µM of
RNase 3/1 (∼1.5 × reduction of the original MIC value) and a
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FIGURE 3 | Biphasic dose-response fit of the variation of the MIC100 of
colistin against A. baumannii as a function of the RNase 3/1 concentration.
The non-linear fitting was done using OriginLab 8.
second plateau at concentrations higher than 10 µM of RNase
3/1 (∼5× reduction of the MIC value).
Exposure of Bacterial Culture to RNase
3/1 Reduces the Acquisition of Bacterial
Resistance to Colistin
Positive synergy results encouraged us to test our hybrid RNase in
an antimicrobial resistance evolution assay. Toward this end, we
performed two different exposure protocols, as described in the
methodology section, which we will refer to as Assays 1 and 2 (see
Figure 4). In Assay 1, we exposed non-treated A. baumannii cells
to either colistin alone or colistin supplemented with RNase 3/1
at 0.1 µM. RNase 3/1 final concentration was selected well below
the minimum value required to display any potential synergy
effect in combination with colistin (see Figure 3). The MIC
value for RNase 3/1 in the assay conditions is ≥10 µM. During
the experiment, in order to increase the selection pressure,
we gradually increased the dose of colistin in accordance to
the bacterial growth, while keeping the same initial RNase 3/1
concentration at 0.1 µM. The cultures of 40 parallel lineages
were serially diluted and transferred for eleven consecutive cycles
of 24-h each, corresponding to a total of about 330 generations
as described (Moffatt et al., 2010). Colistin dose was adjusted
according to the observed bacterial growth curves: the dose was
increased when no effect on the bacterial growth was observed,
and kept constant when a significant reduction of bacterial
growth was registered. The growth of the bacteria following 1/150
dilution was monitored every 5 min and results were compared
to parallel non-exposed control cultures.
Evaluation of the growth curves confirmed that the
experimental evolution assay has been successful. The
monitoring of culture optical density indicated that the exposure
to increasing concentrations of colistin delayed bacterial growth
(see Figure 5). Interestingly, the growth curve displacement is
more pronounced by the addition of RNase 3/1.
Moreover, addition of RNase 3/1 not only displaced the
bacterial growth curve, producing a delay in the overall growth
of the surviving bacterial lineages, but also resulted in increased
mortality rate (see Table 4 and Figure 6A). Noteworthy, the
cycles corresponding to the highest mortality rates (Day 9
and Day 11 in case of colistin alone; Day 4 and Day 11 in
case of colistin combined with RNase 3/1) correlate with an
increase in the time needed to reach the exponential phase.
To note, at the 4th day of exposure, when the colistin dose
was increased from 0.1 to 0.25 µM, we observed a marked
decrease in growth in both colistin and colistin + RNase 3/1
conditions. In particular, the response to the increase of the
colistin dose was most prominent in the RNase 3/1 supplemented
condition, achieving, at 0.25 µM (Day 4), a 20% of mortality
versus only a 2.5% in the cultures exposed only to colistin
(Figure 6A). Likewise, we observed a pronounced shift of the
growth curves (Figures 5, 6B).
A second peak of mortality was visualized between days
8 and 9 (corresponding to 0.35 µM to 0.7 µM of colistin
dose increase). At this point, only 35% of the original
strains exposed to colistin + RNase 3/1 survived, versus a
65% of survival for colistin alone. Interestingly, although the
condition exposed to colistin alone experimented a significant
delay of growth (Figure 6B), this was not the case for
the RNase 3/1 supplemented condition, suggesting that the
surviving strains had already acquired resistance to that
dose of colistin.
Eventually, a shock dose of colistin (10 × the dose of the
previous day) was applied at day 11, triggering a high mortality
and a strong delay of the growth of the surviving strains.
Following this shock dose, the surviving rate of the lineages
exposed to colistin and RNase 3/1 was less than half the observed
in the cultures exposed to colistin alone (35–15% of survival,
respectively), as shown in Figure 6A and Table 4.
On the other hand, results highlighted an overall reduction by
half in the calculated average MIC mean value for colistin in the
bacterial cultures supplemented with RNase 3/1 (Figure 7).
Next, we wanted to explore whether RNase 3/1 addition to
colistin could also hinder the bacterial resistance acquisition
to a strain that had previously acquired resistance to colistin.
With this goal in mind, we incubated an A. baumannii
culture for 3 days in the presence of 0.3 µM of colistin, and
then, we performed a second experimental evolution assay
using this strain, with acquired resistance to colistin, as a
starting seed (see Assay 2 in Figure 4). Then, the cultures
were exposed to either colistin alone or colistin supplemented
with RNase 3/1 at 1 µM final protein concentration. In this
experiment, RNase 3/1 concentration was added at 1 µM
to ensure a positive response when tested in combination
with colistin (see Figure 3). The 40 parallel lineages were
exposed to gradually increasing concentrations of colistin
(1.2-fold following each transfer cycle of 24 h, starting from
an initial concentration of 0.3 µM, see corresponding daily
concentrations in Supplementary Figure S6). The tested colistin
range (from 0.3 to 3.21 µM) ensured the induction of
bacterial resistance and avoided massive cell mortality. Results
indicated that the average increase of the MIC for colistin
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FIGURE 4 | Graphical depiction of the experimental evolution of resistance assay protocol by culture exposure to colistin. 40 parallel lineages of A. baumannii were
exposed to colistin or colistin + RNase 3/1. Assay 1 was started from a single colony without colistin preexposure incubated in the presence of 0.1 µM of RNase
3/1. Assay 2 was started from a culture pre-exposed to 0.3 µM of colistin during 3 days and addition of RNase 3/1 at 1 µM.
FIGURE 5 | A. baumannii growth curves at representative days of exposure. Bacterial culture growth was monitored following 1/150 dilution by OD600 reading.
Points represent the mean of all the lineages for each day and condition. In red is shown the negative control, in blue the colistin-exposed cultures and in green, the
colistin + RNase 3/1 conditions. Error bars represent the standard error of the mean. A statistical analysis was applied to further evaluate the significance of the
observed differences between the behavior of the cultures exposed only to colistin and the cultures exposed to both colistin and RNase 3/1. Taking as a reference
the time needed for the bacteria to reach the exponential phase (OD600 = 0.4), we performed a comparison between cultures belonging to the same cycle
(Figure 6B) and cultures of consecutive cycles within each condition (Supplementary Figures S4, S5).
following 14 cycles of 24 h (about 420 generations) was
significantly decreased for the condition supplemented with
RNase 3/1 in comparison to the non-supplemented sample
(Figure 8 and Supplementary Figure S6).
DISCUSSION
The design of novel strategies for the eradication of bacterial
resistance forms is one of the main concerns of the global health
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TABLE 4 | Evolution of the resistance acquisition of A. baumannii to colistin, considering the number of replicates alive after each day of exposure.
Alive replicates after n days of exposure (%)
D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11
Colistin 100 100 100 97.5 97.5 97.5 97.5 97.5 65 65 35
Colistin
+ RNase 3/1 100 100 100 80 80 80 75 75 35 35 15
Negative control 100 100 100 100 100 100 100 100 100 100 100
Colistin dose 0.1 µM 0.25 µM 0.3 µM 0.35 µM 0.7 µM 2 µM 20 µM
The initial number of replicate lineages was 40. Colistin dose was gradually increased according to bacterial growth, as detailed in the methodology. The colistin dose
used in each exposure is indicated in the bottom row. RNase 3/1, when used, was kept constant at 0.1 µM.
FIGURE 6 | Evolution of the resistance acquisition of A. baumannii to colistin in the presence and absence of RNase 3/1. (A) Graphical representation of the
surviving replicates after each day of exposure. (B) Graphical representation of the time needed for the surviving bacteria upon treatment to reach exponential phase
(OD600 = 0.4). The remaining alive replicates are indicated following each day of exposure. Significance is calculated between the different conditions of the same
day; n.s. means no significance between the compared samples, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001 are indicated. The bottom red line
indicates the calculated MIC of the colistin alone.
organization and is among the top priority lines of action of
the current research policy. The extensive use and abuse of
conventional antibiotics during the last decades have generated
a population of resistant bacteria. This phenomenon has been
aggravated by the fact that most commonly used antibiotics
nowadays are based on bacterial secreted natural products.
Indeed, the pharmaceutical industry has deeply exploited the
naturally produced self-defense toxins that bacteria secrete to
fight against competitor strains. Following billions of years of
co-evolution, a reservoir of resistance genes has been created that
can confer bacterial protection to most conventional antibiotics.
In addition, we cannot underestimate the inherent ability of
bacterial cells to generate diversity. This process can constantly
enrich the bacterial resistome pool, which is easily mobilized in
case of emergency (Blair et al., 2015; Knoppel et al., 2017). Last
but not least, cooperative mechanisms are taking place between
the individual cells of the bacterial community and can provide a
collective antimicrobial resistance profile (Vega and Gore, 2014).
The intercellular network organization can play a prominent
role under stressful conditions and can facilitate an appropriate
response to external injuries. Therefore, the blockage of bacterial
signaling systems should significantly reduce the emergence of
resistance mechanisms. Noteworthy, the horizontal exchange of
material between the integrands of the community is mainly
delivered by bacterial extracellular vesicles. Bacterial extracellular
vesicles ensure the exchange of proteins and nucleic acids (Kulp
and Kuehn, 2010; Rumbo et al., 2011; Schwechheimer and
Kuehn, 2015; Jan, 2017) and mediate the rapid adaption of the
community to hostile environments. Interestingly, the transfer
of RNA molecules has been identified (Guerrero-Mandujano
et al., 2017) to participate in transcription regulation mechanisms
(Sjostrom et al., 2015; Koeppen et al., 2016). Overall, the search
of novel drugs that target the bacterial community signaling
mechanisms, also referred as quorum sensing inhibitors, is
gaining prominence in the pharmaceutical research field.
Within this context, a compound endowed with RNase
activity would be able to interfere in the horizontal exchange
of RNA and thereby attack the community cohesion. To note,
the use of the enzymatic activities of bacteriocin toxins was
proposed as a strategy to weaken the biofilm community
viability (Mathur et al., 2018). Bacteriocins are antimicrobial
proteins secreted by bacteria that specifically target quorum
sensing systems. Among these proteins we can find enzymes
with protease, DNase and RNase activities that facilitate biofilm
removal. Interestingly, recent literature reveals the structure fold
homology between vertebrate secretory RNases and bacterial
RNases that work as inter-strain competition toxins (Batot
et al., 2017; Cuthbert et al., 2018). A parallelism can be
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FIGURE 7 | Comparison of the calculated average mean MIC value following
Assay 1 treatment for RNase 3/1-supplemented versus non-supplemented
bacterial strains exposed to colistin. Error bars show the standard error of the
mean. ∗ indicates that the p-value is < 0.05.
established between bacterial RNases secreted as virulence toxins
and secretory RNases expressed by innate cells in vertebrates
(Lu et al., 2018). An interesting hypothesis puts forward the
scenario where the proteins secreted by granulocytes could
provide a link between a simple local response and a systemic
organized signaling process associated to the increase in size
and complexity of multicellular organisms. In this context,
the host innate cells would have retained similar self-defense
mechanisms as displayed by unicellular organisms. The ancestral
role of bacterial virulence toxins would have derived to a
more specialized role toward body fluid protection against
infection (Lee and Lee, 2005). Understanding the similarities
between unicellular self-defense and mammalian innate cell
mechanisms can provide novel strategies to take profit of our
immune response system. Undoubtedly, our own host defense
system constitutes one of the most attractive sources of novel
antimicrobial agents.
In this work, we have explored the potentiality of an
engineered RNase construct derived from a human antimicrobial
member of the vertebrate-specific RNase A superfamily. Based on
our previous structural-functional studies we have engineered a
hybrid RNase that combines a high catalytic activity together with
specific antimicrobial properties. The RNase 3/1 form conserves
the RNase 1 scaffold that provides the essential requirements
for an elevated catalytic activity (Nogués et al., 1998; Raines,
1998; Doucet et al., 2009; Gagné et al., 2015) and encompasses
the key features of RNase 3 antimicrobial activity (Figure 1)
(Carreras et al., 2003; Boix et al., 2008, 2012; Torrent et al.,
2009a, 2013; Pulido et al., 2013). Experimental results confirmed
that our new construct successfully combines a high catalytic
activity (Figure 2) together with a high bactericidal activity
for all tested Gram-negative species (Table 1). In addition, the
RNase 3/1 variant retained the characteristic high affinity for LPS
of RNase 3 (Torrent et al., 2008) together with its membrane
leakage activity (Torrent et al., 2007, 2009b) (Table 2). On the
other hand, RNase 3/1 shares with RNase 1 its non-toxicity to
the tested human cell lines (Table 3). Indeed, human secretory
RNases’ harmlessness is ensured thanks to the presence in the
cytosol of all human tissue cells of the RNase inhibitor (RI),
a horseshoe-shaped protein that binds to the human secretory
RNase members (Lomax et al., 2014) in a 1:1 stoichiometry
with an unusually high affinity (at the fM-nM range). The RI
is ubiquitous and protects the host cells from the potential
toxicity of secretory RNases (Dickson et al., 2005). Therefore,
our RNase chimera combines a high affinity for bacterial
membranes together with an elevated catalytic efficiency and no
toxicity to the host.
Here, we have investigated the potency of our lead construct
to work as an adjuvant molecule and reduce the emergence
of bacterial resistance to colistin, an antimicrobial peptide,
commonly used in the clinics. Colistin targets bacterial cells
by a direct action at the cell membrane and bacterial wall,
and is mostly used to treat difficult infections, such as the
ones caused by Gram-negative multidrug resistant strains (Stein
and Raoult, 2002; Michalopoulos et al., 2005; Sabuda et al.,
2008; Mendelson et al., 2018). However, colistin can accumulate
in many body tissues, such as kidney and liver, and shows
considerable collateral toxicity to the host in the long term, so
it is only prescribed as a last resort in critically ill patients (Stein
and Raoult, 2002; Michalopoulos et al., 2005; Sabuda et al., 2008;
Mendelson et al., 2018).
The use of drug combinations is currently attracting attention
in the fight against antimicrobial resistance (Tabbene et al., 2015;
Brochado et al., 2018; Lázár et al., 2018). The co-administration
of an adjuvant molecule can significantly lower the required
effective dose to treat an infection. In the same vein, our present
data using A. baumannii cultures indicate that by combining
the engineered RNase construct with colistin we can reduce
its effective dose (Figure 3). Interestingly, this effect shows a
biphasic dose-response profile, with the colistin MIC reaching a
first plateau when it is supplemented with 0.3–5 µM of RNase
3/1 (∼1.5 × decrease of the MIC value) and a second plateau at
concentrations of RNase 3/1 higher than 10 µM (∼5 × decrease
of the MIC). We can hypothesize that this two-step reduction
of the MIC for colistin is due to a dual mechanism of action of
our construct, where a first event is dependent on the protein
enzymatic activity and a second process is triggered by a direct
action against the bacterial cell wall.
Encouraged by the results of the synergy assay we decided
to analyze whether the RNase addition could target the
emergence of bacterial resistance. Toward this end, we set up
an in vitro evolution assay where resistance against colistin
was generated following the culture exposure to increasing
concentrations of the antimicrobial peptide. Forty parallel
lineages of A. baumannii cultures were exposed to increasing
concentrations of colistin from 0.1 to 20 µM. After 330
generations of exposure, we observed a 1.8-fold reduction of
the calculated MIC value for colistin by addition of RNase
3/1. Moreover, when the experimental evolution assay was
started using a colistin-resistant strain, the acquisition of
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FIGURE 8 | Evolution of the mean MIC value for colistin of each assayed condition in Assay 2. Overall reduction of calculated MIC for colistin is observed for samples
supplemented with RNase 3/1. Red corresponds to the negative control, blue to the colistin alone condition and green to the colistin + RNase 3/1 condition. Data
from selected days is shown. The raw data used to produce the figure is shown in Supplementary Figure S6. Error bars show the standard error of the mean.
further resistance to colistin was also significantly delayed by
supplementation of the RNase 3/1 protein.
Results highlight that the RNase 3/1 chimera can significantly
reduce the emergence of bacterial resistance. The construct’s
efficacy to inhibit the emergence of A. baumannii resistance
to colistin at a concentration below its effective bactericidal
activity indicates that the mechanism of action of RNase 3/1
is probably due to a combination of the protein specific
properties and not to a direct bactericidal action. The
present experimental results suggest that the RNase may
act as a double-edged sword, with both enzymatic activity
and membrane disruption/LPS binding being responsible
for the observed phenomenon. Further work is currently
ongoing to determine the specific mechanism underlying
RNase 3/1 reduction of the emergence of bacterial resistance
and ideate additional strategies to enhance its potential
adjuvant properties.
Although further studies will be necessary to confirm
this hypothesis, we speculate that the RNase activity might
interfere with the bacterial community quorum sensing. Since
bacterial resistance to cell-wall targeting antibiotics is often
associated to alterations of the outer membrane composition
(Moffatt et al., 2010; Lázár et al., 2018), an antimicrobial
agent able to block bacterial intercellular communication
should reduce the cell survival adaptation stratagems. In
particular, our RNase 3/1 chimera, with a high binding affinity
to LPS, a positive liposome leakage and high enzymatic
activity, might block the inter-bacterial communication.
However, further testing with other RNase constructs are
mandatory to understand the whole process. Likewise, we
are planning to analyze the potential combinatorial effect
of our RNase construct in the presence of other families of
conventional antibiotics, to discard any specific synergistic
effect unique to the antimicrobial mechanism of colistin.
In addition, to fully interpret our results, it is important to
analyze whether the antibiotic resistome profile differs between
the control exposed to colistin and the RNase 3/1 treated
bacterial cultures.
Our results emphasize once more the applicability of
host defense proteins to design novel anti-infective therapies.
One of the main sources of effective adjuvants is the
host defense arsenal of proteins and peptides. We find
several examples of host defense peptides that are not
antimicrobial by themselves but can boost the host’s innate
immunity. Some of them are currently on clinical trials
for the development of novel adjuvants (Hancock et al.,
2012). Bearing in mind that antibiotic resistance mechanisms
might be palliated but are probably impossible to fully
eradicate (Wright, 2016), alternative strategies to conventional
therapies are urgently needed. Drug combination is nowadays
one of the best choices to combat multidrug resistance
(Brochado et al., 2018). Antibiotic adjuvants can explore
synergy events and significantly reduce the effective antibiotic
dose (Wright, 2016). Although it would be necessary to
fully characterize the mechanism through which RNase 3/1
hinders the bacterial resistance acquisition, RNases and their
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derivatives appear as new lead compounds in the fight against
antimicrobial resistance.
CONCLUSION
Targeting RNA to fight bacterial resistance is a promising
approach toward the development of alternative antibiotic and/or
adjuvant drugs. Our results highlight the ability of an RNase
hybrid protein (RNase 3/1) that combines a high catalytic
activity with specific antimicrobial properties, to display synergic
activity when combined with colistin. Colistin is an antimicrobial
cyclic peptide that is frequently used as a last resort antibiotic
to treat multidrug resistant bacteria in severe infections but
has some toxic side effects. The addition of our RNase lead
compound can significantly reduce the effective antimicrobial
dose of colistin. Moreover, we have demonstrated that the RNase
3/1 construct can efficiently target the bacterial antimicrobial
resistance evolved upon colistin exposure. After 330 generations
of exposure to colistin, we observed about a twofold reduction
of the calculated MIC value when supplementing the culture
with the RNase 3/1 construct. The present data anticipate
the potential development of RNase-based lead molecules as
antibiotic adjuvant candidates.
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